OncLive - Bringing the Oncology Community Together

Premature Aromatase Inhibitor Discontinuation Is Common

Roughly one-third of women with early-stage breast cancer develop intolerable adverse effects during aromatase inhibitor therapy.

Oncology & Biotech News > Clinical Trial Reports

Is There a Best Adjuvant Chemotherapy Regimen for Breast Cancer?

Three prominent breast cancer clinicians and researchers share their opinions on adjuvant anthracyclines, fluoropyrimidines, and taxane agents for women with early breast cancer.

Oncology Live > Conference Highlights

Leading Researcher Sees Turning Point in Breast Cancer: An Interview With José Baselga, MD, PhD

In a six-week span, José Baselga, MD, PhD, notched a stunning series of milestones in breast cancer research that could potentially change practice in different subtypes of the disease.

Oncology Live > Features

Long-Term Breast Cancer Patient Follow-Up Care: Money Well Spent?

J. Michael Dixon, MBChB, MD, and Patrick I. Borgen, MD, discuss the pros and cons of long-term clinical follow-up care of patients with breast cancer.

Oncology Live > Conference Highlights

Identifying Appropriate Patients for HER2-Targeted Therapies

Standards for identifying appropriate populations for treatment with HER2-targeted therapies are evolving.

Conferences > 2012 Oncology Nursing Society Congress

Genetic Assessment of Breast and Ovarian Cancer Risk

Understanding the genetic basis of breast and ovarian cancers is essential to providing patients with effective preventive and/or management strategies that can improve outcomes.

OncLive Nursing > Conference Highlights

Abandoning Old Paradigms: Embracing Molecular Targeting in Breast Cancer Treatments

A discussion with Pat Whitworth, Jr, MD, on how breast cancer treatment has evolved from a 'kitchen sink' approach with chemotherapy to a new paradigm that targets chemosensitivity.

Oncology & Biotech News > Conference Highlights

Collaboration Across Disciplines Driving Progress in Breast Cancer: A Conversation With Debu Tripathy, MD

Debu Tripathy, MD, from the University of Southern California Norris Comprehensive Cancer Center, was one of four co-chairs of the 2012 Miami Breast Cancer Conference.

Oncology & Biotech News > Conference Highlights

Landmark Study Redefines Breast Cancer Into 10 Subtypes

Researchers have determined that breast cancer can be classified into 10 different subtypes instead of four subtypes as previously thought.

> Web Exclusives

Bone Monitoring Is Essential With Exemestane Use for Primary Prevention of Breast Cancer

Monitoring bone health and ensuring adequate calcium and vitamin D intake in postmenopausal women who are taking exemestane for the primary prevention of breast cancer is essential.

Oncology & Biotech News > Clinical Trial Reports

Treatment Patterns of Metastatic Triple-Negative Breast Cancer in US Community Practice Settings

First-line treatment patterns for metastatic triple-negative breast cancer are diverse, reflecting a lack of consensus and an unmet need for standardized therapy.

Contemporary Oncology > Articles

Personalized Medicine: A Promising Future in Oncology Practice

This issue of Contemporary Oncology includes a focus on 2 challenging situations: management of metastatic TNBC and of advanced stage NSCLC.

Contemporary Oncology > From the Editor

Dual Inhibitors Explored in Triple-Negative Tumors

The use of advanced gene analysis techniques in a small group of women with triple-negative metastatic breast cancer has revealed activity in two pathways found in most patients with this subtype.

Oncology Live > Specialty Focus

New Test Provides More Complete Picture of Recurrence Risk for DCIS

A new test specifically designed for breast cancer patients with DCIS appears to be a better indicator of recurrence than other assays for more invasive forms of the disease.

Oncology & Biotech News > Conference Highlights

Patients who undergo chemotherapy for breast cancer may develop fatigue that remains problematic long after they complete treatment.

Oncology & Biotech News > Clinical Trial Reports

Adjuvant Chemotherapy in Breast Cancer—Or Not?

Adjuvant chemotherapy improves disease-free and overall survival in many--but not all--patients with breast cancer.

Oncology & Biotech News > Conference Highlights

Targeted Therapies in Breast Cancer Offer Increasing Hope and Complexity

As research progresses, optimal treatment of breast cancer will involve individualization of therapy to focus on specific targets driving each patient's cancer.

Oncology & Biotech News > Conference Highlights

Molecular Profiling Helps Determine Use of New Therapeutic Agents in Breast Cancer

For locally advanced breast cancer, molecular profiling may be an effective way to determine which patients respond better to certain therapies.

Oncology & Biotech News > Conference Highlights

Supreme Court Asks for Reconsideration on BRCA1 and BRCA2 Patents

The US Supreme Court has asked an appellate court to reconsider its decision regarding patents held on two genes.

> Web Exclusives

Examining the HER2 Testing Puzzle: Fresh Research Explores Nagging Questions

HER2 status in patients with breast cancer has emerged as a durable and effective marker for evaluating tumors and selecting therapies.

Oncology Live > Features